Question 1

What is combined oxidative phosphorylation deficiency 34?

Accepted Answer

Combined oxidative phosphorylation deficiency 34 is a multisystem condition that primarily affects energy metabolism, with key features involving multiple organs such as the liver, endocrine system, and auditory system. Pathogenic variants in the MRPS7 gene disrupt mitochondrial protein synthesis, leading to impaired oxidative phosphorylation. Affected individuals typically present in early life with signs such as congenital sensorineural hearing impairment, increased lactate levels, and hypoglycemia. This condition is very rare, affecting fewer than 1 in 1,000,000 people.

Question 2

What are the symptoms of combined oxidative phosphorylation deficiency 34?

Accepted Answer

The clinical presentation of combined oxidative phosphorylation deficiency 34 involves a constellation of multisystem symptoms. Characteristic findings include an always present increased circulating lactate concentration, congenital sensorineural hearing impairment, hypoglycemia, and hepatic steatosis. Many affected individuals may also experience features such as hypergonadotropic hypogonadism, failure to thrive, and various laboratory abnormalities including elevated thyroid-stimulating hormone, blood urea nitrogen, and creatinine. In a subset of individuals, complications such as primary adrenal insufficiency, lactic acidosis, hepatic failure, vomiting, and hepatomegaly can occur. Not all individuals experience all features, and severity varies considerably.

Question 3

What causes combined oxidative phosphorylation deficiency 34?

Accepted Answer

Combined oxidative phosphorylation deficiency 34 is caused by pathogenic variants in the MRPS7 gene. MRPS7 plays a crucial role in mitochondrial protein synthesis, and disruptions in its function impair energy production within cells. This condition is inherited in an autosomal recessive pattern, meaning that an affected individual must inherit two altered copies of the gene. It is more common when parents share a common ancestor, since the likelihood of both carrying the same rare variant is increased. Genetic counseling is recommended to help families understand the inheritance pattern and assess recurrence risk. Associated genes include MRPS7.

Question 4

How is combined oxidative phosphorylation deficiency 34 inherited?

Accepted Answer

combined oxidative phosphorylation deficiency 34 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How rare is combined oxidative phosphorylation deficiency 34?

Accepted Answer

combined oxidative phosphorylation deficiency 34 is classified as very rare. The estimated prevalence is approximately <1 in 1,000,000. Because rare disease data can be limited, actual numbers may differ from published estimates.

Question 6

How is combined oxidative phosphorylation deficiency 34 diagnosed?

Accepted Answer

Molecular genetic testing is the gold standard for diagnosing combined oxidative phosphorylation deficiency 34. The diagnosis is confirmed through testing that identifies pathogenic variants in the MRPS7 gene, and it is supported by clinical evaluation of characteristic findings such as elevated lactate levels, congenital sensorineural hearing loss, and hypoglycemia. Because many of these symptoms are not unique to this condition, genetic testing is essential to distinguish it from other disorders with overlapping clinical features.

Question 7

Are there treatments for combined oxidative phosphorylation deficiency 34?

Accepted Answer

Currently, management focuses on supportive care and symptom management. There are no specific foundational or approved treatments available for combined oxidative phosphorylation deficiency 34, so treatment is tailored to each individual with attention to multiple organ systems. Multidisciplinary care is recommended, with regular surveillance and monitoring by specialists to help detect complications early. Patients should discuss treatment options with their healthcare team to determine which therapies may be appropriate for their specific situation, and genetic counseling is also advised.

Question 8

What complications can arise from combined oxidative phosphorylation deficiency 34?

Accepted Answer

Individuals with combined oxidative phosphorylation deficiency 34 can experience several complications. These may include primary adrenal insufficiency, lactic acidosis, hepatic failure, vomiting, and hepatomegaly. Not everyone will have all of these complications, and the severity can vary greatly from person to person.

Question 9

How does combined oxidative phosphorylation deficiency 34 affect daily life?

Accepted Answer

Living with combined oxidative phosphorylation deficiency 34 can involve managing various symptoms and complications. Supportive care and regular monitoring by healthcare specialists are important for addressing issues like hypoglycemia and hearing impairment. Families often need to adapt their daily routines to accommodate the needs of affected individuals, including dietary adjustments and regular medical check-ups.

Question 10

What is the prognosis for someone with combined oxidative phosphorylation deficiency 34?

Accepted Answer

The prognosis for combined oxidative phosphorylation deficiency 34 varies widely among individuals. Some may experience stabilization of their condition with early supportive care, while others may see progression of symptoms. Ongoing monitoring and interventions can help improve outcomes, and families are encouraged to stay connected with specialists who understand the condition.

Question 11

Should families consider genetic counseling for combined oxidative phosphorylation deficiency 34?

Accepted Answer

Yes, families should consider genetic counseling when dealing with combined oxidative phosphorylation deficiency 34. Since the condition is inherited in an autosomal recessive pattern, genetic counseling can help families understand the risks of recurrence in future pregnancies. It also provides valuable information about the condition and support for affected individuals and their families.

Research Type	Count	% of Total
Laboratory research	22	58%

Kisho

combined oxidative phosphorylation deficiency 34

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

Recent Publications

combined oxidative phosphorylation deficiency 34

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is combined oxidative phosphorylation deficiency 34?

What are the symptoms of combined oxidative phosphorylation deficiency 34?

What causes combined oxidative phosphorylation deficiency 34?

How is combined oxidative phosphorylation deficiency 34 inherited?

How rare is combined oxidative phosphorylation deficiency 34?

How is combined oxidative phosphorylation deficiency 34 diagnosed?

Are there treatments for combined oxidative phosphorylation deficiency 34?

What complications can arise from combined oxidative phosphorylation deficiency 34?

How does combined oxidative phosphorylation deficiency 34 affect daily life?

What is the prognosis for someone with combined oxidative phosphorylation deficiency 34?

Should families consider genetic counseling for combined oxidative phosphorylation deficiency 34?

Explore clinical features

Recent Publications